Doctors Recommend A New Drug For The Prevention Of HIV Infection

Doctors Recommend A New Drug For The Prevention Of HIV Infection.
Should commoners in peril of contracting HIV because they have dicey sex escort a pill to prevent infection, or will the medication encourage them to take even more erotic risks? After years of debate on this question, a new foreign study suggests the medication doesn't lead consumers to stop using condoms or have more sex with more people. The research isn't definitive, and it hasn't changed the heed of every expert vigrxbox.com. But one of the study's co-authors said the findings reinforcement the drug's use as a progress to prevent infection with HIV, the virus that causes AIDS.

And "People may have more partners or stem using condoms, but as well as we can tell, it's not because of taking the drug to baffle HIV infection ," said study co-author Dr Robert Grant, a major investigator with the Gladstone Institute of Virology and Immunology in San Francisco. The medication in dispute is called Truvada, which combines the drugs emtricitabine and tenofovir. It's normally worn to wine and dine people who are infected with HIV, but fact-finding - in gay and bisexual men and in straight couples with one infected accomplice - have shown that it can lower the risk of infection in populace who become exposed to the virus through sex.

However, it does not eliminate the risk of infection. The US Food and Drug Administration approved the poison for avoiding purposes in 2012. Few people seem to be taking it for halt purposes, however. Its manufacturer, Gilead, has disclosed that about 1700 commonality are taking the drug for that reason in the United States, Grant said. In the different study, researchers found that expected rates of HIV and syphilis infection decreased in almost 2500 men and transgender women when they took Truvada.

The haunt participants, who all faced tainted gamble of HIV infection, were recruited in Peru, Ecuador, South Africa, Brazil, Thailand and the United States. Some of the participants took Truvada while others took an supine placebo. Those who believed they were taking Truvada "were just as uninjured as all else," Grant said, suggesting that they weren't more promising to abandon using condoms or be more promiscuous because they believed they had extra protection against HIV infection.

Grant said the sketch of the study allows scientists to better the hang of the choices that participants make. The study is limited, however, because the researchers recruited participants a substitute of waiting for people to come to them. For that reason, it's farcical to know if tribe will seek out Truvada to take new levels of risk by, say, no longer using condoms. There are many skeptics, including the AIDS Healthcare Foundation, who fears that the cure-all will ingenuously stimulate people to make riskier decisions in regard to sex.

One of these skeptics is Arleen Leibowitz, a professor emeritus of conspicuous policy at the Luskin School of Public Affairs at the University of California, Los Angeles. She said the survey shows that many persons failed to effect Truvada as prescribed and often didn't take enough to be protected from HIV. That raises the expectancy that some people would take risks because they assume they're protected when they actually aren't, she noted.

Leibowitz also said some of the statistics in the cramming are questionable because they don't include enough participants. And she said the participants may have lied about their slang screwing lives to satisfy the people who interviewed them. "We'll learn a lot when its use becomes more general. But it's pathetic to do experiments on the general population".

For the moment, she said, the sedative may be appropriate for some patients who need buffer from HIV, but doctors should be cautious and make sure their patients cart the medication. The study is published in the Dec 18, 2013 online version of the journal PLoS One 4rx box. In other HIV/AIDS news, a unknown study - also published in PLoS One - reports that 20-year-old men infected with HIV in the United States and Canada can foresee to white-hot almost as elongate as the general population and make it, typically, to their early 70s.